Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.06 -0.31 (-1.18%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

5 Must-Read Analyst Questions From Amphastar Pharmaceuticals’s Q3 Earnings Call

November 13, 2025

Amphastar Pharmaceuticals' third quarter results for 2025 came in ahead of Wall Street's revenue and profit expectations, despite essentially flat sales compared to the prior year. The quarter was...

Via StockStory

Topics Earnings

Reflecting On Generic Pharmaceuticals Stocks’ Q3 Earnings: Viatris (NASDAQ:VTRS)

November 12, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today

November 12, 2025

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial...

Via StockStory

Topics Artificial Intelligence Supply Chain

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best

November 11, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today

November 10, 2025

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.9% in the afternoon session after the stock's positive momentum continued as the company reported third-quarter...

Via StockStory

Topics Artificial Intelligence Supply Chain

AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures

November 10, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $191.8 million. Its non-GAAP...

Via StockStory

Why Amphastar Pharmaceuticals (AMPH) Stock Is Up Today

November 07, 2025

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 4.9% in the afternoon session after the company reported third-quarter 2025 financial results that surpassed analyst...

Via StockStory

Topics Artificial Intelligence Economy Government

The Analyst Verdict: Amphastar Pharma In The Eyes Of 4 Experts ↗

November 07, 2025

Via Benzinga

Amphastar Pharmaceuticals (NASDAQ:AMPH) Delivers Strong Q3 Numbers

November 06, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $191.8 million. Its non-GAAP profit...

Via StockStory

Topics Artificial Intelligence Supply Chain

Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect

November 04, 2025

Via StockStory

1 of Wall Street’s Favorite Stock to Target This Week and 2 That Underwhelm

October 30, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

Topics Economy

2 Reasons AMPH is Risky and 1 Stock to Buy Instead

October 27, 2025

Since April 2025, Amphastar Pharmaceuticals has been in a holding pattern, floating around $24.52. The stock also fell short of the S&P 500’s 22.9% gain during that period.

Via StockStory

Topics Economy Government Stocks

Demystifying Amphastar Pharma: Insights From 4 Analyst Reviews ↗

October 22, 2025

Via Benzinga

Align Technology, Envista, Centene, Amphastar Pharmaceuticals, and Oscar Health Shares Plummet, What You Need To Know

October 10, 2025

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.

Via StockStory

Topics Economy Government World Trade

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

3 Stocks Under $50 We’re Skeptical Of

October 07, 2025

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

3 Value Stocks with Warning Signs

October 06, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Value Investor's Opportunity ↗

October 01, 2025

Amphastar Pharmaceuticals appears undervalued with a low P/E ratio, strong profitability, and solid financial health, fitting value investing criteria.

Via Chartmill

3 Low-Volatility Stocks with Open Questions

September 24, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

3 Small-Cap Stocks That Concern Us

September 19, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Presents a Compelling Value Investment Case ↗

September 09, 2025

Amphastar Pharmaceuticals (AMPH) is a value stock with strong profitability, a low P/E ratio, and solid financial health, trading below intrinsic value.

Via Chartmill

A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack

September 04, 2025

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Profitable Stocks We Steer Clear Of

August 29, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Value Stock with Strong Fundamentals and Undervalued Potential ↗

August 18, 2025

Amphastar Pharmaceuticals (AMPH) offers strong value potential with low P/E ratios, high profitability, and stable finances, making it a solid pick for value investors seeking undervalued stocks.

Via Chartmill

Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know

August 12, 2025

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed...

Via StockStory

Topics Bonds Economy Lawsuit

Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum ↗

August 12, 2025

FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch.

Via Benzinga

Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6%

August 08, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 4.4% year on year to $174.4 million. Its non-GAAP profit...

Via StockStory

Amphastar (AMPH) Q2 2025 Earnings Call Transcript ↗

August 07, 2025

Via The Motley Fool

Topics Earnings Supply Chain

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

Headline News about Amphastar Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today